#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Altered	_
1-2	8-17	brainstem	_
1-3	18-27	responses	_
1-4	28-30	to	_
1-5	31-40	modafinil	_
1-6	41-43	in	_
1-7	44-57	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-8	58-59	:	_
1-9	60-72	implications	_
1-10	73-76	for	_
1-11	77-87	adjunctive	_
1-12	88-97	treatment	_
1-13	98-100	of	_
1-14	101-110	cognition	_
1-15	111-120	Candidate	_
1-16	121-134	pro-cognitive	_
1-17	135-140	drugs	_
1-18	141-144	for	_
1-19	145-158	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-20	159-168	targeting	_
1-21	169-176	several	_
1-22	177-190	neurochemical	_
1-23	191-198	systems	_
1-24	199-203	have	_
1-25	204-216	consistently	_
1-26	217-223	failed	_
1-27	224-226	to	_
1-28	227-238	demonstrate	_
1-29	239-245	robust	_
1-30	246-254	efficacy	_
1-31	255-256	.	_

2-1	257-259	It	_
2-2	260-267	remains	_
2-3	268-276	untested	_
2-4	277-284	whether	_
2-5	285-295	concurrent	_
2-6	296-309	antipsychotic	_
2-7	310-321	medications	_
2-8	322-327	exert	_
2-9	328-343	pharmacodynamic	_
2-10	344-356	interactions	_
2-11	357-361	that	_
2-12	362-370	mitigate	_
2-13	371-384	pro-cognitive	_
2-14	385-391	action	_
2-15	392-394	in	_
2-16	395-403	patients	_
2-17	404-405	.	_

3-1	406-408	We	_
3-2	409-413	used	_
3-3	414-424	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
3-4	425-428	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
3-5	429-430	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
3-6	431-435	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
3-7	436-437	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
3-8	438-440	in	_
3-9	441-442	a	_
3-10	443-453	randomized	_
3-11	454-455	,	_
3-12	456-468	double-blind	_
3-13	469-470	,	_
3-14	471-489	placebo-controlled	_
3-15	490-504	within-subject	_
3-16	505-514	crossover	_
3-17	515-519	test	_
3-18	520-522	of	_
3-19	523-534	single-dose	_
3-20	535-544	modafinil	_
3-21	545-552	effects	_
3-22	553-555	in	_
3-23	556-558	27	_
3-24	559-568	medicated	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-25	569-582	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-26	583-591	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-27	592-593	,	_
3-28	594-607	interrogating	_
3-29	608-617	brainstem	_
3-30	618-625	regions	_
3-31	626-631	where	_
3-32	632-645	catecholamine	_
3-33	646-653	systems	_
3-34	654-659	arise	_
3-35	660-662	to	_
3-36	663-672	innervate	_
3-37	673-676	the	_
3-38	677-683	cortex	_
3-39	684-685	,	_
3-40	686-688	to	_
3-41	689-693	link	_
3-42	694-702	cellular	_
3-43	703-706	and	_
3-44	707-720	systems-level	_
3-45	721-727	models	_
3-46	728-730	of	_
3-47	731-740	cognitive	_
3-48	741-748	control	_
3-49	749-750	.	_

4-1	751-760	Modafinil	_
4-2	761-768	effects	_
4-3	769-773	were	_
4-4	774-783	evaluated	_
4-5	784-788	both	_
4-6	789-795	within	_
4-7	796-800	this	_
4-8	801-808	patient	_
4-9	809-814	group	_
4-10	815-818	and	_
4-11	819-827	compared	_
4-12	828-830	to	_
4-13	831-832	a	_
4-14	833-840	healthy	_
4-15	841-848	subject	_
4-16	849-854	group	_
4-17	855-856	.	_

5-1	857-866	Modafinil	_
5-2	867-876	modulated	_
5-3	877-885	activity	_
5-4	886-888	in	_
5-5	889-892	the	_
5-6	893-898	locus	_
5-7	899-908	coeruleus	_
5-8	909-910	(	_
5-9	911-913	LC	_
5-10	914-915	)	_
5-11	916-919	and	_
5-12	920-927	ventral	_
5-13	928-937	tegmental	_
5-14	938-942	area	_
5-15	943-944	(	_
5-16	945-948	VTA	_
5-17	949-950	)	_
5-18	951-953	in	_
5-19	954-957	the	_
5-20	958-965	patient	_
5-21	966-971	group	_
5-22	972-973	.	_

6-1	974-981	However	_
6-2	982-983	,	_
6-3	984-992	compared	_
6-4	993-995	to	_
6-5	996-999	the	_
6-6	1000-1007	healthy	_
6-7	1008-1018	comparison	_
6-8	1019-1024	group	_
6-9	1025-1026	,	_
6-10	1027-1032	these	_
6-11	1033-1040	effects	_
6-12	1041-1045	were	_
6-13	1046-1053	altered	_
6-14	1054-1056	as	_
6-15	1057-1058	a	_
6-16	1059-1067	function	_
6-17	1068-1070	of	_
6-18	1071-1075	task	_
6-19	1076-1083	demands	_
6-20	1084-1085	:	_
6-21	1086-1089	the	_
6-22	1090-1109	control-independent	_
6-23	1110-1114	drug	_
6-24	1115-1121	effect	_
6-25	1122-1124	on	_
6-26	1125-1137	deactivation	_
6-27	1138-1141	was	_
6-28	1142-1152	relatively	_
6-29	1153-1163	attenuated	_
6-30	1164-1165	(	_
6-31	1166-1175	shallower	_
6-32	1176-1177	)	_
6-33	1178-1180	in	_
6-34	1181-1184	the	_
6-35	1185-1187	LC	_
6-36	1188-1191	and	_
6-37	1192-1203	exaggerated	_
6-38	1204-1205	(	_
6-39	1206-1212	deeper	_
6-40	1213-1214	)	_
6-41	1215-1217	in	_
6-42	1218-1221	the	_
6-43	1222-1225	VTA	_
6-44	1226-1227	;	_
6-45	1228-1230	in	_
6-46	1231-1239	contrast	_
6-47	1240-1241	,	_
6-48	1242-1247	again	_
6-49	1248-1256	compared	_
6-50	1257-1259	to	_
6-51	1260-1263	the	_
6-52	1264-1274	comparison	_
6-53	1275-1280	group	_
6-54	1281-1282	,	_
6-55	1283-1286	the	_
6-56	1287-1302	control-related	_
6-57	1303-1307	drug	_
6-58	1308-1315	effects	_
6-59	1316-1318	on	_
6-60	1319-1327	positive	_
6-61	1328-1338	activation	_
6-62	1339-1343	were	_
6-63	1344-1354	attenuated	_
6-64	1355-1357	in	_
6-65	1358-1360	LC	_
6-66	1361-1362	,	_
6-67	1363-1366	VTA	_
6-68	1367-1370	and	_
6-69	1371-1374	the	_
6-70	1375-1383	cortical	_
6-71	1384-1393	cognitive	_
6-72	1394-1401	control	_
6-73	1402-1409	network	_
6-74	1410-1411	.	_

7-1	1412-1417	These	_
7-2	1418-1425	altered	_
7-3	1426-1433	effects	_
7-4	1434-1436	in	_
7-5	1437-1440	the	_
7-6	1441-1443	LC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-7	1444-1447	and	_
7-8	1448-1451	VTA	_
7-9	1452-1456	were	_
7-10	1457-1470	significantly	_
7-11	1471-1474	and	_
7-12	1475-1487	specifically	_
7-13	1488-1498	associated	_
7-14	1499-1503	with	_
7-15	1504-1507	the	_
7-16	1508-1514	degree	_
7-17	1515-1517	of	_
7-18	1518-1528	antagonism	_
7-19	1529-1531	of	_
7-20	1532-1539	alpha-2	_
7-21	1540-1550	adrenergic	_
7-22	1551-1554	and	_
7-23	1555-1565	dopamine-2	_
7-24	1566-1575	receptors	_
7-25	1576-1577	,	_
7-26	1578-1590	respectively	_
7-27	1591-1592	,	_
7-28	1593-1595	by	_
7-29	1596-1608	concurrently	_
7-30	1609-1619	prescribed	_
7-31	1620-1634	antipsychotics	_
7-32	1635-1636	.	_

8-1	1637-1642	These	_
8-2	1643-1650	sources	_
8-3	1651-1653	of	_
8-4	1654-1662	evidence	_
8-5	1663-1670	suggest	_
8-6	1671-1682	interacting	_
8-7	1683-1690	effects	_
8-8	1691-1693	on	_
8-9	1694-1707	catecholamine	_
8-10	1708-1715	neurons	_
8-11	1716-1718	of	_
8-12	1719-1726	chronic	_
8-13	1727-1740	antipsychotic	_
8-14	1741-1750	treatment	_
8-15	1751-1752	,	_
8-16	1753-1758	which	_
8-17	1759-1771	respectively	_
8-18	1772-1780	increase	_
8-19	1781-1784	and	_
8-20	1785-1793	decrease	_
8-21	1794-1803	sustained	_
8-22	1804-1812	neuronal	_
8-23	1813-1821	activity	_
8-24	1822-1824	in	_
8-25	1825-1827	LC	_
8-26	1828-1831	and	_
8-27	1832-1835	VTA	_
8-28	1836-1837	.	_

9-1	1838-1842	This	_
9-2	1843-1845	is	_
9-3	1846-1849	the	_
9-4	1850-1855	first	_
9-5	1856-1862	direct	_
9-6	1863-1871	evidence	_
9-7	1872-1874	in	_
9-8	1875-1876	a	_
9-9	1877-1885	clinical	_
9-10	1886-1896	population	_
9-11	1897-1899	to	_
9-12	1900-1907	suggest	_
9-13	1908-1912	that	_
9-14	1913-1926	antipsychotic	_
9-15	1927-1938	medications	_
9-16	1939-1944	alter	_
9-17	1945-1958	catecholamine	_
9-18	1959-1967	neuronal	_
9-19	1968-1976	activity	_
9-20	1977-1979	to	_
9-21	1980-1988	mitigate	_
9-22	1989-2002	pro-cognitive	_
9-23	2003-2007	drug	_
9-24	2008-2014	action	_
9-25	2015-2017	on	_
9-26	2018-2026	cortical	_
9-27	2027-2035	circuits	_
9-28	2036-2037	.	_

10-1	2038-2046	Subjects	_
10-2	2047-2050	and	_
10-3	2051-2058	methods	_
10-4	2059-2076	Subjects/overview	_
10-5	2077-2079	of	_
10-6	2080-2090	procedures	_
10-7	2091-2094	The	_
10-8	2095-2100	study	_
10-9	2101-2104	was	_
10-10	2105-2108	set	_
10-11	2109-2111	in	_
10-12	2112-2115	the	_
10-13	2116-2126	University	_
10-14	2127-2129	of	_
10-15	2130-2146	Californiaâ€”Davis	_
10-16	2147-2154	Medical	_
10-17	2155-2161	Center	_
10-18	2162-2166	from	_
10-19	2167-2175	February	_
10-20	2176-2180	2007	_
10-21	2181-2183	to	_
10-22	2184-2188	July	_
10-23	2189-2193	2010	_
10-24	2194-2195	.	_

11-1	2196-2199	The	_
11-2	2200-2218	ClinicalTrials.gov	_
11-3	2219-2229	identifier	_
11-4	2230-2232	is	_
11-5	2233-2244	NCT00423943	_
11-6	2245-2246	.	_

12-1	2247-2250	All	_
12-2	2251-2261	procedures	_
12-3	2262-2266	were	_
12-4	2267-2275	approved	_
12-5	2276-2278	by	_
12-6	2279-2282	the	_
12-7	2283-2286	UCD	_
12-8	2287-2300	Institutional	_
12-9	2301-2307	Review	_
12-10	2308-2313	Board	_
12-11	2314-2315	.	_

13-1	2316-2319	All	_
13-2	2320-2328	subjects	_
13-3	2329-2337	provided	_
13-4	2338-2346	informed	_
13-5	2347-2354	consent	_
13-6	2355-2358	for	_
13-7	2359-2362	all	_
13-8	2363-2373	procedures	_
13-9	2374-2375	,	_
13-10	2376-2379	and	_
13-11	2380-2388	received	_
13-12	2389-2401	remuneration	_
13-13	2402-2405	for	_
13-14	2406-2416	procedures	_
13-15	2417-2418	,	_
13-16	2419-2422	and	_
13-17	2423-2426	the	_
13-18	2427-2432	study	_
13-19	2433-2436	was	_
13-20	2437-2446	concluded	_
13-21	2447-2449	at	_
13-22	2450-2453	the	_
13-23	2454-2457	end	_
13-24	2458-2460	of	_
13-25	2461-2464	the	_
13-26	2465-2472	funding	_
13-27	2473-2478	award	_
13-28	2479-2485	period	_
13-29	2486-2487	.	_

14-1	2488-2493	There	_
14-2	2494-2498	were	_
14-3	2499-2501	no	_
14-4	2502-2509	changes	_
14-5	2510-2512	to	_
14-6	2513-2516	the	_
14-7	2517-2524	methods	_
14-8	2525-2527	or	_
14-9	2528-2536	outcomes	_
14-10	2537-2542	after	_
14-11	2543-2548	trial	_
14-12	2549-2561	commencement	_
14-13	2562-2563	.	_

15-1	2564-2572	Subjects	_
15-2	2573-2577	were	_
15-3	2578-2581	all	_
15-4	2582-2593	outpatients	_
15-5	2594-2595	,	_
15-6	2596-2605	recruited	_
15-7	2606-2610	from	_
15-8	2611-2614	the	_
15-9	2615-2624	community	_
15-10	2625-2628	and	_
15-11	2629-2632	our	_
15-12	2633-2641	research	_
15-13	2642-2648	clinic	_
15-14	2649-2651	at	_
15-15	2652-2655	UCD	_
15-16	2656-2657	,	_
15-17	2658-2661	and	_
15-18	2662-2666	were	_
15-19	2667-2675	included	_
15-20	2676-2678	if	_
15-21	2679-2683	they	_
15-22	2684-2688	were	_
15-23	2689-2693	aged	_
15-24	2694-2699	18â€“50	_
15-25	2700-2705	years	_
15-26	2706-2707	,	_
15-27	2708-2711	and	_
15-28	2712-2718	lacked	_
15-29	2719-2722	the	_
15-30	2723-2732	following	_
15-31	2733-2740	history	_
15-32	2741-2742	:	_
15-33	2743-2755	neurological	_
15-34	2756-2763	illness	_
15-35	2764-2765	,	_
15-36	2766-2775	including	_
15-37	2776-2780	head	_
15-38	2781-2787	injury	_
15-39	2788-2792	with	_
15-40	2793-2797	loss	_
15-41	2798-2800	of	_
15-42	2801-2814	consciousness	_
15-43	2815-2816	,	_
15-44	2817-2830	uncorrectable	_
15-45	2831-2837	visual	_
15-46	2838-2840	or	_
15-47	2841-2851	peripheral	_
15-48	2852-2857	motor	_
15-49	2858-2869	disturbance	_
15-50	2870-2871	;	_
15-51	2872-2882	full-scale	_
15-52	2883-2885	IQ	_
15-53	2886-2887	<	_
15-54	2888-2890	70	_
15-55	2891-2892	(	_
15-56	2893-2895	by	_
15-57	2896-2904	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-58	2905-2916	Abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-59	2917-2922	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-60	2923-2925	of	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-61	2926-2938	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-62	2939-2940	:	_
15-63	2941-2945	WASI	_
15-64	2946-2947	)	_
15-65	2948-2949	;	_
15-66	2950-2955	known	_
15-67	2956-2967	intolerance	_
15-68	2968-2970	to	_
15-69	2971-2980	modafinil	_
15-70	2981-2982	;	_
15-71	2983-2989	active	_
15-72	2990-2999	substance	_
15-73	3000-3005	abuse	_
15-74	3006-3012	within	_
15-75	3013-3014	6	_
15-76	3015-3021	months	_
15-77	3022-3024	of	_
15-78	3025-3030	study	_
15-79	3031-3032	;	_
15-80	3033-3045	uncontrolled	_
15-81	3046-3053	medical	_
15-82	3054-3061	illness	_
15-83	3062-3063	;	_
15-84	3064-3079	incompatability	_
15-85	3080-3084	with	_
15-86	3085-3088	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-87	3089-3099	procedures	_
15-88	3100-3101	.	_

16-1	3102-3105	All	_
16-2	3106-3114	patients	_
16-3	3115-3119	were	_
16-4	3120-3129	evaluated	_
16-5	3130-3132	by	_
16-6	3133-3143	structured	_
16-7	3144-3154	diagnostic	_
16-8	3155-3164	interview	_
16-9	3165-3166	,	_
16-10	3167-3172	using	_
16-11	3173-3176	the	_
16-12	3177-3183	SCID-I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-13	3184-3188	with	_
16-14	3189-3198	DSM-IV-TR	_
16-15	3199-3207	criteria	_
16-16	3208-3209	,	_
16-17	3210-3213	and	_
16-18	3214-3217	all	_
16-19	3218-3226	assigned	_
16-20	3227-3228	a	_
16-21	3229-3234	295.X	_
16-22	3235-3244	diagnosis	_
16-23	3245-3246	.	_

17-1	3247-3251	Each	_
17-2	3252-3259	subject	_
17-3	3260-3269	completed	_
17-4	3270-3271	a	_
17-5	3272-3284	double-blind	_
17-6	3285-3286	,	_
17-7	3287-3305	placebo-controlled	_
17-8	3306-3315	crossover	_
17-9	3316-3321	study	_
17-10	3322-3324	of	_
17-11	3325-3334	modafinil	_
17-12	3335-3336	(	_
17-13	3337-3343	single	_
17-14	3344-3348	oral	_
17-15	3349-3353	dose	_
17-16	3354-3357	200	_
17-17	3358-3360	mg	_
17-18	3361-3362	)	_
17-19	3363-3370	effects	_
17-20	3371-3373	on	_
17-21	3374-3380	neural	_
17-22	3381-3389	activity	_
17-23	3390-3398	measured	_
17-24	3399-3401	by	_
17-25	3402-3406	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
17-26	3407-3413	during	_
17-27	3414-3423	cognitive	_
17-28	3424-3431	control	_
17-29	3432-3436	task	_
17-30	3437-3448	performance	_
17-31	3449-3450	.	_

18-1	3451-3455	BOLD	_
18-2	3456-3462	signal	_
18-3	3463-3469	change	_
18-4	3470-3478	measured	_
18-5	3479-3481	by	_
18-6	3482-3486	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
18-7	3487-3493	during	_
18-8	3494-3497	the	_
18-9	3498-3507	cognitive	_
18-10	3508-3512	task	_
18-11	3513-3516	was	_
18-12	3517-3520	the	_
18-13	3521-3528	primary	_
18-14	3529-3536	outcome	_
18-15	3537-3544	measure	_
18-16	3545-3546	,	_
18-17	3547-3550	and	_
18-18	3551-3555	task	_
18-19	3556-3567	performance	_
18-20	3568-3571	was	_
18-21	3572-3575	the	_
18-22	3576-3585	secondary	_
18-23	3586-3593	outcome	_
18-24	3594-3601	measure	_
18-25	3602-3603	.	_

19-1	3604-3606	To	_
19-2	3607-3614	address	_
19-3	3615-3625	concurrent	_
19-4	3626-3636	medication	_
19-5	3637-3644	effects	_
19-6	3645-3647	in	_
19-7	3648-3656	relation	_
19-8	3657-3659	to	_
19-9	3660-3667	altered	_
19-10	3668-3677	modafinil	_
19-11	3678-3685	effects	_
19-12	3686-3688	on	_
19-13	3689-3693	BOLD	_
19-14	3694-3700	signal	_
19-15	3701-3707	change	_
19-16	3708-3709	,	_
19-17	3710-3712	we	_
19-18	3713-3717	also	_
19-19	3718-3725	derived	_
19-20	3726-3734	measures	_
19-21	3735-3737	of	_
19-22	3738-3748	medication	_
19-23	3749-3753	load	_
19-24	3754-3756	at	_
19-25	3757-3770	catecholamine	_
19-26	3771-3783	autoreceptor	_
19-27	3784-3792	subtypes	_
19-28	3793-3794	,	_
19-29	3795-3804	conferred	_
19-30	3805-3807	by	_
19-31	3808-3811	the	_
19-32	3812-3825	schizophrenia	_
19-33	3826-3834	patients	_
19-34	3835-3836	â€™	_
19-35	3837-3846	treatment	_
19-36	3847-3855	regimens	_
19-37	3856-3857	,	_
19-38	3858-3860	as	_
19-39	3861-3871	determined	_
19-40	3872-3874	by	_
19-41	3875-3884	published	_
19-42	3885-3893	standard	_
19-43	3894-3901	indices	_
19-44	3902-3904	of	_
19-45	3905-3907	in	_
19-46	3908-3913	vitro	_
19-47	3914-3927	catecholamine	_
19-48	3928-3936	receptor	_
19-49	3937-3945	activity	_
19-50	3946-3947	(	_
19-51	3948-3951	see	_
19-52	3952-3962	Supplement	_
19-53	3963-3964	)	_
19-54	3965-3966	.	_

20-1	3967-3969	We	_
20-2	3970-3976	tested	_
20-3	3977-3982	these	_
20-4	3983-3995	hypothesized	_
20-5	3996-4009	relationships	_
20-6	4010-4012	by	_
20-7	4013-4024	correlating	_
20-8	4025-4035	concurrent	_
20-9	4036-4046	medication	_
20-10	4047-4052	loads	_
20-11	4053-4057	with	_
20-12	4058-4064	neural	_
20-13	4065-4074	responses	_
20-14	4075-4077	to	_
20-15	4078-4087	modafinil	_
20-16	4088-4089	,	_
20-17	4090-4092	as	_
20-18	4093-4095	an	_
20-19	4096-4106	additional	_
20-20	4107-4116	secondary	_
20-21	4117-4124	outcome	_
20-22	4125-4132	measure	_
20-23	4133-4134	.	_

21-1	4135-4143	Tertiary	_
21-2	4144-4151	outcome	_
21-3	4152-4160	measures	_
21-4	4161-4169	included	_
21-5	4170-4180	subjective	_
21-6	4181-4186	state	_
21-7	4187-4195	measured	_
21-8	4196-4200	with	_
21-9	4201-4204	the	_
21-10	4205-4209	POMS	_
21-11	4210-4211	,	_
21-12	4212-4215	and	_
21-13	4216-4221	vital	_
21-14	4222-4227	signs	_
21-15	4228-4236	measured	_
21-16	4237-4241	with	_
21-17	4242-4243	a	_
21-18	4244-4249	blood	_
21-19	4250-4258	pressure	_
21-20	4259-4263	cuff	_
21-21	4264-4265	.	_

22-1	4266-4271	While	_
22-2	4272-4276	this	_
22-3	4277-4280	was	_
22-4	4281-4283	an	_
22-5	4284-4297	unprecedented	_
22-6	4298-4299	,	_
22-7	4300-4311	preliminary	_
22-8	4312-4317	study	_
22-9	4318-4319	,	_
22-10	4320-4326	sample	_
22-11	4327-4331	size	_
22-12	4332-4335	was	_
22-13	4336-4348	approximated	_
22-14	4349-4354	based	_
22-15	4355-4357	on	_
22-16	4358-4362	both	_
22-17	4363-4374	preliminary	_
22-18	4375-4382	results	_
22-19	4383-4387	from	_
22-20	4388-4391	the	_
22-21	4392-4399	healthy	_
22-22	4400-4410	comparison	_
22-23	4411-4416	group	_
22-24	4417-4420	and	_
22-25	4421-4423	an	_
22-26	4424-4431	earlier	_
22-27	4432-4441	published	_
22-28	4442-4447	study	_
22-29	4448-4450	of	_
22-30	4451-4460	modafinil	_
22-31	4461-4468	effects	_
22-32	4469-4471	on	_
22-33	4472-4482	prefrontal	_
22-34	4483-4491	cortical	_
22-35	4492-4500	function	_
22-36	4501-4502	.	_

23-1	4503-4506	See	_
23-2	4507-4519	Supplemental	_
23-3	4520-4527	Methods	_
23-4	4528-4531	for	_
23-5	4532-4542	additional	_
23-6	4543-4549	detail	_
23-7	4550-4552	on	_
23-8	4553-4556	the	_
23-9	4557-4567	evaluation	_
23-10	4568-4570	of	_
23-11	4571-4579	subjects	_
23-12	4580-4581	.	_

24-1	4582-4591	Cognitive	_
24-2	4592-4600	Paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-3	4601-4604	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-4	4605-4614	Preparing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-5	4615-4617	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-6	4618-4626	Overcome	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-7	4627-4637	Prepotency	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-8	4638-4639	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-9	4640-4643	POP	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-10	4644-4645	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-11	4646-4650	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-12	4651-4652	(	_
24-13	4653-4665	Supplemental	_
24-14	4666-4669	Fig	_
24-15	4670-4671	.	_

25-1	4672-4673	1	_
25-2	4674-4675	)	_
25-3	4676-4679	was	_
25-4	4680-4689	presented	_
25-5	4690-4695	using	_
25-6	4696-4702	EPrime	_
25-7	4703-4711	software	_
25-8	4712-4713	.	_

26-1	4714-4716	In	_
26-2	4717-4721	this	_
26-3	4722-4726	task	_
26-4	4727-4728	,	_
26-5	4729-4730	a	_
26-6	4731-4737	visual	_
26-7	4738-4741	cue	_
26-8	4742-4743	(	_
26-9	4744-4747	Red	_
26-10	4748-4750	or	_
26-11	4751-4756	Green	_
26-12	4757-4762	color	_
26-13	4763-4770	patches	_
26-14	4771-4772	,	_
26-15	4773-4776	500	_
26-16	4777-4779	ms	_
26-17	4780-4788	duration	_
26-18	4789-4790	)	_
26-19	4791-4793	in	_
26-20	4794-4797	the	_
26-21	4798-4804	center	_
26-22	4805-4807	of	_
26-23	4808-4811	the	_
26-24	4812-4818	visual	_
26-25	4819-4824	field	_
26-26	4825-4834	instructs	_
26-27	4835-4836	a	_
26-28	4837-4854	stimulus-response	_
26-29	4855-4856	(	_
26-30	4857-4860	Sâ€“R	_
26-31	4861-4862	)	_
26-32	4863-4870	mapping	_
26-33	4871-4873	to	_
26-34	4874-4877	the	_
26-35	4878-4883	probe	_
26-36	4884-4885	,	_
26-37	4886-4891	which	_
26-38	4892-4898	occurs	_
26-39	4899-4904	after	_
26-40	4905-4906	a	_
26-41	4907-4912	delay	_
26-42	4913-4914	(	_
26-43	4915-4918	7.5	_
26-44	4919-4920	s	_
26-45	4921-4926	delay	_
26-46	4927-4931	from	_
26-47	4932-4935	cue	_
26-48	4936-4942	offset	_
26-49	4943-4945	to	_
26-50	4946-4951	probe	_
26-51	4952-4957	onset	_
26-52	4958-4959	)	_
26-53	4960-4961	.	_

27-1	4962-4965	The	_
27-2	4966-4971	probe	_
27-3	4972-4974	is	_
27-4	4975-4977	an	_
27-5	4978-4983	arrow	_
27-6	4984-4988	that	_
27-7	4989-4995	occurs	_
27-8	4996-5000	with	_
27-9	5001-5006	equal	_
27-10	5007-5016	frequency	_
27-11	5017-5025	pointing	_
27-12	5026-5028	to	_
27-13	5029-5032	the	_
27-14	5033-5037	left	_
27-15	5038-5040	or	_
27-16	5041-5046	right	_
27-17	5047-5048	,	_
27-18	5049-5058	presented	_
27-19	5059-5061	in	_
27-20	5062-5065	the	_
27-21	5066-5072	center	_
27-22	5073-5075	of	_
27-23	5076-5079	the	_
27-24	5080-5086	visual	_
27-25	5087-5092	field	_
27-26	5093-5096	for	_
27-27	5097-5100	500	_
27-28	5101-5103	ms	_
27-29	5104-5106	in	_
27-30	5107-5115	duration	_
27-31	5116-5117	.	_

28-1	5118-5121	The	_
28-2	5122-5131	direction	_
28-3	5132-5134	of	_
28-4	5135-5138	the	_
28-5	5139-5144	arrow	_
28-6	5145-5150	probe	_
28-7	5151-5153	is	_
28-8	5154-5164	randomized	_
28-9	5165-5167	to	_
28-10	5168-5176	preclude	_
28-11	5177-5180	the	_
28-12	5181-5192	preparation	_
28-13	5193-5195	of	_
28-14	5196-5204	specific	_
28-15	5205-5210	motor	_
28-16	5211-5220	responses	_
28-17	5221-5223	in	_
28-18	5224-5227	the	_
28-19	5228-5237	cue-probe	_
28-20	5238-5243	delay	_
28-21	5244-5250	period	_
28-22	5251-5252	.	_

29-1	5253-5256	The	_
29-2	5257-5265	response	_
29-3	5266-5272	demand	_
29-4	5273-5275	is	_
29-5	5276-5285	prepotent	_
29-6	5286-5289	for	_
29-7	5290-5300	Green-cued	_
29-8	5301-5307	trials	_
29-9	5308-5309	(	_
29-10	5310-5314	i.e.	_
29-11	5315-5316	,	_
29-12	5317-5320	the	_
29-13	5321-5328	correct	_
29-14	5329-5337	response	_
29-15	5338-5340	is	_
29-16	5341-5342	a	_
29-17	5343-5347	left	_
29-18	5348-5360	button-press	_
29-19	5361-5364	for	_
29-20	5365-5373	leftward	_
29-21	5374-5380	arrows	_
29-22	5381-5382	,	_
29-23	5383-5386	and	_
29-24	5387-5392	right	_
29-25	5393-5396	for	_
29-26	5397-5402	right	_
29-27	5403-5404	)	_
29-28	5405-5406	,	_
29-29	5407-5410	and	_
29-30	5411-5413	is	_
29-31	5414-5427	non-prepotent	_
29-32	5428-5431	for	_
29-33	5432-5440	Red-cued	_
29-34	5441-5447	trials	_
29-35	5448-5449	(	_
29-36	5450-5454	i.e.	_
29-37	5455-5456	,	_
29-38	5457-5461	left	_
29-39	5462-5474	button-press	_
29-40	5475-5478	for	_
29-41	5479-5488	rightward	_
29-42	5489-5495	arrows	_
29-43	5496-5497	,	_
29-44	5498-5501	and	_
29-45	5502-5506	vice	_
29-46	5507-5512	versa	_
29-47	5513-5514	)	_
29-48	5515-5516	.	_

30-1	5517-5520	The	_
30-2	5521-5527	period	_
30-3	5528-5532	from	_
30-4	5533-5538	probe	_
30-5	5539-5544	onset	_
30-6	5545-5547	to	_
30-7	5548-5551	cue	_
30-8	5552-5557	onset	_
30-9	5558-5560	of	_
30-10	5561-5564	the	_
30-11	5565-5575	successive	_
30-12	5576-5581	trial	_
30-13	5582-5584	is	_
30-14	5585-5587	12	_
30-15	5588-5590	s.	_
30-16	5591-5597	During	_
30-17	5598-5602	both	_
30-18	5603-5612	cue-probe	_
30-19	5613-5618	delay	_
30-20	5619-5622	and	_
30-21	5623-5632	probe-cue	_
30-22	5633-5641	interval	_
30-23	5642-5643	,	_
30-24	5644-5652	subjects	_
30-25	5653-5656	are	_
30-26	5657-5667	instructed	_
30-27	5668-5670	to	_
30-28	5671-5677	fixate	_
30-29	5678-5686	visually	_
30-30	5687-5689	on	_
30-31	5690-5691	a	_
30-32	5692-5701	crosshair	_
30-33	5702-5711	presented	_
30-34	5712-5714	in	_
30-35	5715-5718	the	_
30-36	5719-5725	center	_
30-37	5726-5728	of	_
30-38	5729-5732	the	_
30-39	5733-5739	visual	_
30-40	5740-5745	field	_
30-41	5746-5747	.	_

31-1	5748-5752	Four	_
31-2	5753-5759	blocks	_
31-3	5760-5764	with	_
31-4	5765-5767	20	_
31-5	5768-5774	trials	_
31-6	5775-5779	each	_
31-7	5780-5784	were	_
31-8	5785-5794	performed	_
31-9	5795-5796	,	_
31-10	5797-5801	with	_
31-11	5802-5812	randomized	_
31-12	5813-5818	order	_
31-13	5819-5821	of	_
31-14	5822-5826	cues	_
31-15	5827-5828	,	_
31-16	5829-5831	70	_
31-17	5832-5833	%	_
31-18	5834-5836	of	_
31-19	5837-5842	which	_
31-20	5843-5847	were	_
31-21	5848-5857	comprised	_
31-22	5858-5860	of	_
31-23	5861-5870	prepotent	_
31-24	5871-5872	(	_
31-25	5873-5883	Green-cued	_
31-26	5884-5885	)	_
31-27	5886-5889	Sâ€“R	_
31-28	5890-5898	mappings	_
31-29	5899-5900	,	_
31-30	5901-5904	and	_
31-31	5905-5909	each	_
31-32	5910-5915	block	_
31-33	5916-5923	lasting	_
31-34	5924-5925	6	_
31-35	5926-5929	min	_
31-36	5930-5932	40	_
31-37	5933-5935	s.	_
31-38	5936-5944	Subjects	_
31-39	5945-5949	were	_
31-40	5950-5960	instructed	_
31-41	5961-5963	to	_
31-42	5964-5965	â€˜	_
31-43	5966-5968	go	_
31-44	5969-5971	as	_
31-45	5972-5976	fast	_
31-46	5977-5979	as	_
31-47	5980-5983	you	_
31-48	5984-5987	can	_
31-49	5988-5995	without	_
31-50	5996-6002	making	_
31-51	6003-6012	mistakes.	_
31-52	6013-6014	â€™	_
31-53	6015-6018	The	_
31-54	6019-6022	POP	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
31-55	6023-6027	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
31-56	6028-6036	requires	_
31-57	6037-6046	cognitive	_
31-58	6047-6054	control	_
31-59	6055-6057	to	_
31-60	6058-6066	overcome	_
31-61	6067-6068	a	_
31-62	6069-6078	prepotent	_
31-63	6079-6096	stimulus-response	_
31-64	6097-6104	mapping	_
31-65	6105-6106	.	_

32-1	6107-6119	High-control	_
32-2	6120-6127	demands	_
32-3	6128-6129	(	_
32-4	6130-6138	Red-cued	_
32-5	6139-6145	trials	_
32-6	6146-6147	)	_
32-7	6148-6151	are	_
32-8	6152-6162	associated	_
32-9	6163-6167	with	_
32-10	6168-6178	decrements	_
32-11	6179-6180	(	_
32-12	6181-6186	costs	_
32-13	6187-6188	)	_
32-14	6189-6191	in	_
32-15	6192-6200	response	_
32-16	6201-6209	accuracy	_
32-17	6210-6213	and	_
32-18	6214-6219	speed	_
32-19	6220-6221	,	_
32-20	6222-6225	and	_
32-21	6226-6232	robust	_
32-22	6233-6241	activity	_
32-23	6242-6244	of	_
32-24	6245-6248	the	_
32-25	6249-6256	lateral	_
32-26	6257-6260	and	_
32-27	6261-6267	medial	_
32-28	6268-6271	PFC	_
32-29	6272-6278	during	_
32-30	6279-6282	the	_
32-31	6283-6294	preparatory	_
32-32	6295-6304	cue-probe	_
32-33	6305-6310	delay	_
32-34	6311-6317	period	_
32-35	6318-6319	.	_

33-1	6320-6324	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-2	6325-6336	Acquisition	_
33-3	6337-6340	and	_
33-4	6341-6355	Pre-processing	_
33-5	6356-6369	Event-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
33-6	6370-6374	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-7	6375-6378	was	_
33-8	6379-6388	conducted	_
33-9	6389-6391	on	_
33-10	6392-6393	a	_
33-11	6394-6395	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-12	6396-6401	tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-13	6402-6409	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-14	6410-6414	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-15	6415-6418	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-16	6419-6425	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-17	6426-6430	with	_
33-18	6431-6432	a	_
33-19	6433-6440	Siemens	_
33-20	6441-6450	8-channel	_
33-21	6451-6457	phased	_
33-22	6458-6463	array	_
33-23	6464-6468	coil	_
33-24	6469-6470	.	_

34-1	6471-6482	Measurement	_
34-2	6483-6485	of	_
34-3	6486-6491	Blood	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
34-4	6492-6498	Oxygen	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
34-5	6499-6514	Level-Dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
34-6	6515-6516	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
34-7	6517-6521	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
34-8	6522-6523	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
34-9	6524-6532	contrast	_
34-10	6533-6536	was	_
34-11	6537-6546	conducted	_
34-12	6547-6553	during	_
34-13	6554-6565	single-shot	_
34-14	6566-6567	,	_
34-15	6568-6579	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-16	6580-6587	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-17	6588-6589	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-18	6590-6593	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-19	6594-6595	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
34-20	6596-6597	,	_
34-21	6598-6603	using	_
34-22	6604-6605	a	_
34-23	6606-6608	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-24	6609-6610	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-25	6611-6620	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-26	6621-6629	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-27	6630-6631	,	_
34-28	6632-6635	and	_
34-29	6636-6647	whole-brain	_
34-30	6648-6656	coverage	_
34-31	6657-6658	.	_

35-1	6659-6662	The	_
35-2	6663-6673	parameters	_
35-3	6674-6676	of	_
35-4	6677-6680	the	_
35-5	6681-6684	EPI	_
35-6	6685-6693	sequence	_
35-7	6694-6698	were	_
35-8	6699-6701	TR	_
35-9	6702-6706	2000	_
35-10	6707-6709	ms	_
35-11	6710-6711	,	_
35-12	6712-6714	TE	_
35-13	6715-6717	30	_
35-14	6718-6720	ms	_
35-15	6721-6722	,	_
35-16	6723-6727	flip	_
35-17	6728-6733	angle	_
35-18	6734-6737	90Â°	_
35-19	6738-6739	,	_
35-20	6740-6743	FOV	_
35-21	6744-6747	220	_
35-22	6748-6749	Ã—	_
35-23	6750-6753	220	_
35-24	6754-6756	mm	_
35-25	6757-6758	,	_
35-26	6759-6763	with	_
35-27	6764-6766	36	_
35-28	6767-6777	contiguous	_
35-29	6778-6784	slices	_
35-30	6785-6787	in	_
35-31	6788-6791	the	_
35-32	6792-6797	axial	_
35-33	6798-6805	oblique	_
35-34	6806-6811	plane	_
35-35	6812-6816	with	_
35-36	6817-6822	voxel	_
35-37	6823-6827	size	_
35-38	6828-6831	3.4	_
35-39	6832-6834	mm	_
35-40	6835-6844	isotropic	_
35-41	6845-6846	.	_

36-1	6847-6849	In	_
36-2	6850-6858	addition	_
36-3	6859-6860	,	_
36-4	6861-6862	a	_
36-5	6863-6873	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
36-6	6874-6877	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
36-7	6878-6881	was	_
36-8	6882-6890	acquired	_
36-9	6891-6894	for	_
36-10	6895-6908	normalization	_
36-11	6909-6911	of	_
36-12	6912-6915	EPI	_
36-13	6916-6922	images	_
36-14	6923-6925	to	_
36-15	6926-6929	the	_
36-16	6930-6938	template	_
36-17	6939-6940	,	_
36-18	6941-6946	using	_
36-19	6947-6948	a	_
36-20	6949-6971	Magnetization-Prepared	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-21	6972-6977	Rapid	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-22	6978-6986	Acquired	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-23	6987-6995	Gradient	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-24	6996-7000	Echo	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-25	7001-7002	(	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-26	7003-7010	MP-RAGE	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-27	7011-7012	)	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-28	7013-7021	sequence	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
36-29	7022-7023	,	_
36-30	7024-7028	with	_
36-31	7029-7032	the	_
36-32	7033-7042	following	_
36-33	7043-7053	parameters	_
36-34	7054-7055	:	_
36-35	7056-7058	TR	_
36-36	7059-7063	2500	_
36-37	7064-7066	ms	_
36-38	7067-7068	,	_
36-39	7069-7071	TE	_
36-40	7072-7076	4.82	_
36-41	7077-7079	ms	_
36-42	7080-7081	,	_
36-43	7082-7093	acquisition	_
36-44	7094-7098	time	_
36-45	7099-7103	9:20	_
36-46	7104-7105	,	_
36-47	7106-7110	flip	_
36-48	7111-7116	angle	_
36-49	7117-7119	7Â°	_
36-50	7120-7121	,	_
36-51	7122-7125	FOV	_
36-52	7126-7129	256	_
36-53	7130-7131	Ã—	_
36-54	7132-7135	256	_
36-55	7136-7138	mm	_
36-56	7139-7140	,	_
36-57	7141-7145	with	_
36-58	7146-7149	192	_
36-59	7150-7156	slices	_
36-60	7157-7158	1	_
36-61	7159-7161	mm	_
36-62	7162-7167	thick	_
36-63	7168-7169	.	_

37-1	7170-7184	Pre-processing	_
37-2	7185-7188	and	_
37-3	7189-7197	analysis	_
37-4	7198-7200	of	_
37-5	7201-7204	EPI	_
37-6	7205-7211	images	_
37-7	7212-7216	were	_
37-8	7217-7226	performed	_
37-9	7227-7232	using	_
37-10	7233-7237	SPM5	_
37-11	7238-7239	.	_

38-1	7240-7243	The	_
38-2	7244-7249	first	_
38-3	7250-7254	four	_
38-4	7255-7261	images	_
38-5	7262-7263	(	_
38-6	7264-7273	preceding	_
38-7	7274-7279	onset	_
38-8	7280-7282	of	_
38-9	7283-7288	trial	_
38-10	7289-7292	one	_
38-11	7293-7295	of	_
38-12	7296-7301	block	_
38-13	7302-7305	one	_
38-14	7306-7307	)	_
38-15	7308-7312	were	_
38-16	7313-7322	discarded	_
38-17	7323-7325	to	_
38-18	7326-7331	allow	_
38-19	7332-7335	for	_
38-20	7336-7349	stabilization	_
38-21	7350-7352	of	_
38-22	7353-7356	the	_
38-23	7357-7364	scanner	_
38-24	7365-7371	signal	_
38-25	7372-7373	.	_

39-1	7374-7377	The	_
39-2	7378-7387	remaining	_
39-3	7388-7394	images	_
39-4	7395-7399	were	_
39-5	7400-7409	realigned	_
39-6	7410-7411	(	_
39-7	7412-7428	motion-corrected	_
39-8	7429-7430	)	_
39-9	7431-7433	to	_
39-10	7434-7437	the	_
39-11	7438-7443	first	_
39-12	7444-7452	retained	_
39-13	7453-7458	image	_
39-14	7459-7461	in	_
39-15	7462-7465	the	_
39-16	7466-7471	first	_
39-17	7472-7477	block	_
39-18	7478-7479	,	_
39-19	7480-7483	and	_
39-20	7484-7492	adjusted	_
39-21	7493-7496	for	_
39-22	7497-7508	acquisition	_
39-23	7509-7513	time	_
39-24	7514-7515	(	_
39-25	7516-7521	slice	_
39-26	7522-7528	timing	_
39-27	7529-7539	correction	_
39-28	7540-7541	)	_
39-29	7542-7543	.	_

40-1	7544-7546	At	_
40-2	7547-7551	this	_
40-3	7552-7557	point	_
40-4	7558-7559	,	_
40-5	7560-7575	skull-stripping	_
40-6	7576-7579	was	_
40-7	7580-7589	performed	_
40-8	7590-7592	on	_
40-9	7593-7597	both	_
40-10	7598-7605	MP-RAGE	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
40-11	7606-7612	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
40-12	7613-7616	and	_
40-13	7617-7620	the	_
40-14	7621-7635	single-subject	_
40-15	7636-7638	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-16	7639-7647	template	_
40-17	7648-7652	from	_
40-18	7653-7656	SPM	_
40-19	7657-7658	.	_

41-1	7659-7662	The	_
41-2	7663-7670	MP-RAGE	_
41-3	7671-7676	image	_
41-4	7677-7681	from	_
41-5	7682-7686	each	_
41-6	7687-7694	subject	_
41-7	7695-7698	was	_
41-8	7699-7712	co-registered	_
41-9	7713-7715	to	_
41-10	7716-7719	the	_
41-11	7720-7722	T1	_
41-12	7723-7731	template	_
41-13	7732-7734	to	_
41-14	7735-7744	determine	_
41-15	7745-7758	normalization	_
41-16	7759-7769	parameters	_
41-17	7770-7771	,	_
41-18	7772-7777	which	_
41-19	7778-7782	were	_
41-20	7783-7787	then	_
41-21	7788-7795	applied	_
41-22	7796-7798	to	_
41-23	7799-7803	each	_
41-24	7804-7807	EPI	_
41-25	7808-7813	image	_
41-26	7814-7817	for	_
41-27	7818-7822	that	_
41-28	7823-7830	subject	_
41-29	7831-7834	via	_
41-30	7835-7846	6-parameter	_
41-31	7847-7857	rigid-body	_
41-32	7858-7864	affine	_
41-33	7865-7879	transformation	_
41-34	7880-7882	to	_
41-35	7883-7891	standard	_
41-36	7892-7895	MNI	_
41-37	7896-7901	space	_
41-38	7902-7903	.	_

42-1	7904-7910	Images	_
42-2	7911-7915	were	_
42-3	7916-7920	then	_
42-4	7921-7929	resliced	_
42-5	7930-7932	to	_
42-6	7933-7934	2	_
42-7	7935-7936	Ã—	_
42-8	7937-7938	2	_
42-9	7939-7940	Ã—	_
42-10	7941-7942	2	_
42-11	7943-7946	and	_
42-12	7947-7956	spatially	_
42-13	7957-7965	smoothed	_
42-14	7966-7970	with	_
42-15	7971-7973	an	_
42-16	7974-7975	8	_
42-17	7976-7978	mm	_
42-18	7979-7980	,	_
42-19	7981-8007	full-width-at-half-maximum	_
42-20	8008-8016	Gaussian	_
42-21	8017-8023	kernel	_
42-22	8024-8025	.	_

43-1	8026-8028	At	_
43-2	8029-8033	this	_
43-3	8034-8039	point	_
43-4	8040-8041	,	_
43-5	8042-8046	Drug	_
43-6	8047-8050	and	_
43-7	8051-8058	Placebo	_
43-8	8059-8062	day	_
43-9	8063-8068	scans	_
43-10	8069-8073	were	_
43-11	8074-8086	concatenated	_
43-12	8087-8090	for	_
43-13	8091-8099	modeling	_
43-14	8100-8102	of	_
43-15	8103-8106	the	_
43-16	8107-8113	signal	_
43-17	8114-8117	and	_
43-18	8118-8129	inferential	_
43-19	8130-8137	testing	_
43-20	8138-8139	.	_

44-1	8140-8148	Modeling	_
44-2	8149-8152	and	_
44-3	8153-8164	inferential	_
44-4	8165-8172	testing	_
44-5	8173-8175	of	_
44-6	8176-8186	voxel-wise	_
44-7	8187-8191	drug	_
44-8	8192-8199	effects	_
44-9	8200-8202	on	_
44-10	8203-8209	neural	_
44-11	8210-8218	activity	_
44-12	8219-8229	Derivation	_
44-13	8230-8232	of	_
44-14	8233-8236	the	_
44-15	8237-8243	signal	_
44-16	8244-8253	proceeded	_
44-17	8254-8258	with	_
44-18	8259-8262	the	_
44-19	8263-8266	use	_
44-20	8267-8269	of	_
44-21	8270-8273	the	_
44-22	8274-8281	General	_
44-23	8282-8288	Linear	_
44-24	8289-8294	Model	_
44-25	8295-8296	.	_

45-1	8297-8307	Regressors	_
45-2	8308-8312	were	_
45-3	8313-8324	established	_
45-4	8325-8328	for	_
45-5	8329-8341	Drug_RedCues	_
45-6	8342-8343	,	_
45-7	8344-8358	Drug_GreenCues	_
45-8	8359-8360	,	_
45-9	8361-8376	Placebo_RedCues	_
45-10	8377-8378	,	_
45-11	8379-8382	and	_
45-12	8383-8400	Placebo_GreenCues	_
45-13	8401-8402	,	_
45-14	8403-8406	and	_
45-15	8407-8416	analogous	_
45-16	8417-8427	regressors	_
45-17	8428-8431	for	_
45-18	8432-8438	Probes	_
45-19	8439-8440	.	_

46-1	8441-8443	We	_
46-2	8444-8448	also	_
46-3	8449-8457	included	_
46-4	8458-8459	a	_
46-5	8460-8468	nuisance	_
46-6	8469-8478	regressor	_
46-7	8479-8482	for	_
46-8	8483-8489	errors	_
46-9	8490-8493	and	_
46-10	8494-8500	trials	_
46-11	8501-8508	lacking	_
46-12	8509-8510	a	_
46-13	8511-8516	motor	_
46-14	8517-8525	response	_
46-15	8526-8527	,	_
46-16	8528-8530	to	_
46-17	8531-8538	account	_
46-18	8539-8542	for	_
46-19	8543-8548	these	_
46-20	8549-8562	event-related	_
46-21	8563-8569	signal	_
46-22	8570-8577	changes	_
46-23	8578-8579	,	_
46-24	8580-8583	but	_
46-25	8584-8587	did	_
46-26	8588-8591	not	_
46-27	8592-8599	include	_
46-28	8600-8605	these	_
46-29	8606-8608	in	_
46-30	8609-8612	the	_
46-31	8613-8624	inferential	_
46-32	8625-8632	testing	_
46-33	8633-8634	,	_
46-34	8635-8637	as	_
46-35	8638-8642	they	_
46-36	8643-8647	were	_
46-37	8648-8651	too	_
46-38	8652-8656	rare	_
46-39	8657-8660	for	_
46-40	8661-8669	reliable	_
46-41	8670-8678	analysis	_
46-42	8679-8680	(	_
46-43	8681-8684	see	_
46-44	8685-8689	task	_
46-45	8690-8701	performance	_
46-46	8702-8709	results	_
46-47	8710-8711	)	_
46-48	8712-8713	.	_

47-1	8714-8715	A	_
47-2	8716-8725	canonical	_
47-3	8726-8727	(	_
47-4	8728-8743	double-Gaussian	_
47-5	8744-8745	)	_
47-6	8746-8757	hemodynamic	_
47-7	8758-8766	response	_
47-8	8767-8775	function	_
47-9	8776-8779	was	_
47-10	8780-8789	convolved	_
47-11	8790-8794	with	_
47-12	8795-8796	a	_
47-13	8797-8803	series	_
47-14	8804-8806	of	_
47-15	8807-8812	delta	_
47-16	8813-8822	functions	_
47-17	8823-8825	to	_
47-18	8826-8831	model	_
47-19	8832-8835	the	_
47-20	8836-8840	BOLD	_
47-21	8841-8845	time	_
47-22	8846-8852	series	_
47-23	8853-8854	,	_
47-24	8855-8859	with	_
47-25	8860-8870	regressors	_
47-26	8871-8877	placed	_
47-27	8878-8880	at	_
47-28	8881-8884	cue	_
47-29	8885-8888	and	_
47-30	8889-8894	probe	_
47-31	8895-8900	onset	_
47-32	8901-8902	.	_

48-1	8903-8905	We	_
48-2	8906-8910	also	_
48-3	8911-8922	established	_
48-4	8923-8926	the	_
48-5	8927-8935	temporal	_
48-6	8936-8946	derivative	_
48-7	8947-8949	of	_
48-8	8950-8953	the	_
48-9	8954-8957	HRF	_
48-10	8958-8960	as	_
48-11	8961-8962	a	_
48-12	8963-8972	regressor	_
48-13	8973-8974	,	_
48-14	8975-8981	paired	_
48-15	8982-8986	with	_
48-16	8987-8991	each	_
48-17	8992-8994	of	_
48-18	8995-8998	the	_
48-19	8999-9011	experimental	_
48-20	9012-9021	condition	_
48-21	9022-9032	regressors	_
48-22	9033-9034	,	_
48-23	9035-9037	to	_
48-24	9038-9045	account	_
48-25	9046-9049	for	_
48-26	9050-9058	temporal	_
48-27	9059-9068	variation	_
48-28	9069-9071	in	_
48-29	9072-9075	the	_
48-30	9076-9083	latency	_
48-31	9084-9086	of	_
48-32	9087-9090	the	_
48-33	9091-9104	event-related	_
48-34	9105-9113	response	_
48-35	9114-9115	.	_

49-1	9116-9117	A	_
49-2	9118-9124	0.0125	_
49-3	9125-9127	Hz	_
49-4	9128-9137	high-pass	_
49-5	9138-9144	filter	_
49-6	9145-9148	was	_
49-7	9149-9153	used	_
49-8	9154-9155	,	_
49-9	9156-9157	a	_
49-10	9158-9169	first-order	_
49-11	9170-9184	autoregressive	_
49-12	9185-9193	function	_
49-13	9194-9196	to	_
49-14	9197-9204	account	_
49-15	9205-9208	for	_
49-16	9209-9215	serial	_
49-17	9216-9232	autocorrelations	_
49-18	9233-9234	,	_
49-19	9235-9238	and	_
49-20	9239-9244	grand	_
49-21	9245-9249	mean	_
49-22	9250-9257	scaling	_
49-23	9258-9260	to	_
49-24	9261-9268	account	_
49-25	9269-9272	for	_
49-26	9273-9279	global	_
49-27	9280-9291	differences	_
49-28	9292-9294	in	_
49-29	9295-9301	signal	_
49-30	9302-9307	value	_
49-31	9308-9314	across	_
49-32	9315-9319	test	_
49-33	9320-9324	days	_
49-34	9325-9326	.	_

50-1	9327-9332	After	_
50-2	9333-9339	signal	_
50-3	9340-9350	estimation	_
50-4	9351-9352	,	_
50-5	9353-9359	linear	_
50-6	9360-9369	contrasts	_
50-7	9370-9374	were	_
50-8	9375-9382	defined	_
50-9	9383-9385	at	_
50-10	9386-9389	the	_
50-11	9390-9404	single-subject	_
50-12	9405-9410	level	_
50-13	9411-9412	(	_
50-14	9413-9416	see	_
50-15	9417-9422	below	_
50-16	9423-9424	)	_
50-17	9425-9426	,	_
50-18	9427-9430	and	_
50-19	9431-9435	then	_
50-20	9436-9444	relevant	_
50-21	9445-9453	contrast	_
50-22	9454-9458	maps	_
50-23	9459-9463	from	_
50-24	9464-9474	individual	_
50-25	9475-9483	subjects	_
50-26	9484-9485	(	_
50-27	9486-9496	containing	_
50-28	9497-9507	voxel-wise	_
50-29	9508-9517	parameter	_
50-30	9518-9527	estimates	_
50-31	9528-9531	for	_
50-32	9532-9533	a	_
50-33	9534-9539	given	_
50-34	9540-9548	contrast	_
50-35	9549-9550	)	_
50-36	9551-9555	were	_
50-37	9556-9563	entered	_
50-38	9564-9568	into	_
50-39	9569-9580	group-level	_
50-40	9581-9589	analysis	_
50-41	9590-9593	for	_
50-42	9594-9605	inferential	_
50-43	9606-9613	testing	_
50-44	9614-9615	.	_

51-1	9616-9619	The	_
51-2	9620-9639	control-independent	_
51-3	9640-9649	Treatment	_
51-4	9650-9656	effect	_
51-5	9657-9660	was	_
51-6	9661-9667	tested	_
51-7	9668-9672	with	_
51-8	9673-9676	the	_
51-9	9677-9685	contrast	_
51-10	9686-9693	defined	_
51-11	9694-9696	as	_
51-12	9697-9698	(	_
51-13	9699-9710	Drug_RedCue	_
51-14	9711-9712	+	_
51-15	9713-9726	Drug_GreenCue	_
51-16	9727-9728	)	_
51-17	9729-9730	>	_
51-18	9731-9732	(	_
51-19	9733-9747	Placebo_RedCue	_
51-20	9748-9749	+	_
51-21	9750-9766	Placebo_GreenCue	_
51-22	9767-9768	)	_
51-23	9769-9770	.	_

52-1	9771-9775	This	_
52-2	9776-9784	contrast	_
52-3	9785-9789	uses	_
52-4	9790-9793	all	_
52-5	9794-9803	available	_
52-6	9804-9808	data	_
52-7	9809-9811	to	_
52-8	9812-9820	estimate	_
52-9	9821-9830	treatment	_
52-10	9831-9838	effects	_
52-11	9839-9843	that	_
52-12	9844-9847	are	_
52-13	9848-9859	independent	_
52-14	9860-9862	of	_
52-15	9863-9867	Task	_
52-16	9868-9877	Condition	_
52-17	9878-9879	,	_
52-18	9880-9884	i.e.	_
52-19	9885-9886	,	_
52-20	9887-9896	cognitive	_
52-21	9897-9904	control	_
52-22	9905-9912	demands	_
52-23	9913-9914	.	_

53-1	9915-9917	We	_
53-2	9918-9930	hypothesized	_
53-3	9931-9935	that	_
53-4	9936-9938	in	_
53-5	9939-9943	this	_
53-6	9944-9952	contrast	_
53-7	9953-9954	,	_
53-8	9955-9966	significant	_
53-9	9967-9971	drug	_
53-10	9972-9979	effects	_
53-11	9980-9981	(	_
53-12	9982-9990	relative	_
53-13	9991-9993	to	_
53-14	9994-10001	placebo	_
53-15	10002-10003	)	_
53-16	10004-10009	would	_
53-17	10010-10012	be	_
53-18	10013-10021	manifest	_
53-19	10022-10024	as	_
53-20	10025-10038	deactivations	_
53-21	10039-10041	in	_
53-22	10042-10046	both	_
53-23	10047-10050	the	_
53-24	10051-10053	LC	_
53-25	10054-10057	and	_
53-26	10058-10061	the	_
53-27	10062-10065	VTA	_
53-28	10066-10067	,	_
53-29	10068-10077	attendant	_
53-30	10078-10080	to	_
53-31	10081-10084	the	_
53-32	10085-10090	model	_
53-33	10091-10093	of	_
53-34	10094-10107	catecholamine	_
53-35	10108-10125	neurotransmission	_
53-36	10126-10128	at	_
53-37	10129-10133	cell	_
53-38	10134-10140	bodies	_
53-39	10141-10142	,	_
53-40	10143-10145	an	_
53-41	10146-10152	effect	_
53-42	10153-10169	well-established	_
53-43	10170-10173	for	_
53-44	10174-10187	catecholamine	_
53-45	10188-10199	transporter	_
53-46	10200-10210	inhibitors	_
53-47	10211-10215	such	_
53-48	10216-10218	as	_
53-49	10219-10229	stimulants	_
53-50	10230-10233	and	_
53-51	10234-10249	antidepressants	_
53-52	10250-10251	.	_

54-1	10252-10254	In	_
54-2	10255-10263	contrast	_
54-3	10264-10265	,	_
54-4	10266-10269	for	_
54-5	10270-10273	the	_
54-6	10274-10289	control-related	_
54-7	10290-10299	treatment	_
54-8	10300-10306	effect	_
54-9	10307-10309	on	_
54-10	10310-10315	brain	_
54-11	10316-10324	activity	_
54-12	10325-10326	,	_
54-13	10327-10330	the	_
54-14	10331-10339	contrast	_
54-15	10340-10343	was	_
54-16	10344-10355	established	_
54-17	10356-10358	as	_
54-18	10359-10360	(	_
54-19	10361-10372	Drug_RedCue	_
54-20	10373-10378	minus	_
54-21	10379-10392	Drug_GreenCue	_
54-22	10393-10394	)	_
54-23	10395-10396	>	_
54-24	10397-10398	(	_
54-25	10399-10413	Placebo_RedCue	_
54-26	10414-10419	minus	_
54-27	10420-10436	Placebo_GreenCue	_
54-28	10437-10438	)	_
54-29	10439-10440	.	_

55-1	10441-10445	This	_
55-2	10446-10448	is	_
55-3	10449-10458	analogous	_
55-4	10459-10461	to	_
55-5	10462-10463	a	_
55-6	10464-10475	directional	_
55-7	10476-10480	test	_
55-8	10481-10483	of	_
55-9	10484-10487	the	_
55-10	10488-10505	Treatment-by-Task	_
55-11	10506-10515	Condition	_
55-12	10516-10527	interaction	_
55-13	10528-10530	in	_
55-14	10531-10536	ANOVA	_
55-15	10537-10548	terminology	_
55-16	10549-10550	,	_
55-17	10551-10554	and	_
55-18	10555-10557	in	_
55-19	10558-10562	this	_
55-20	10563-10571	contrast	_
55-21	10572-10573	,	_
55-22	10574-10576	we	_
55-23	10577-10589	hypothesized	_
55-24	10590-10594	that	_
55-25	10595-10598	the	_
55-26	10599-10603	Drug	_
55-27	10604-10609	would	_
55-28	10610-10615	serve	_
55-29	10616-10618	to	_
55-30	10619-10629	positively	_
55-31	10630-10637	enhance	_
55-32	10638-10640	LC	_
55-33	10641-10644	and	_
55-34	10645-10648	VTA	_
55-35	10649-10657	activity	_
55-36	10658-10659	.	_

56-1	10660-10664	This	_
56-2	10665-10667	is	_
56-3	10668-10675	because	_
56-4	10676-10683	despite	_
56-5	10684-10685	a	_
56-6	10686-10705	control-independent	_
56-7	10706-10712	effect	_
56-8	10713-10715	of	_
56-9	10716-10720	Drug	_
56-10	10721-10729	manifest	_
56-11	10730-10732	as	_
56-12	10733-10745	deactivation	_
56-13	10746-10747	,	_
56-14	10748-10751	the	_
56-15	10752-10756	drug	_
56-16	10757-10763	should	_
56-17	10764-10771	augment	_
56-18	10772-10775	the	_
56-19	10776-10784	positive	_
56-20	10785-10795	difference	_
56-21	10796-10798	in	_
56-22	10799-10807	activity	_
56-23	10808-10815	related	_
56-24	10816-10818	to	_
56-25	10819-10828	cognitive	_
56-26	10829-10836	control	_
56-27	10837-10844	demands	_
56-28	10845-10846	(	_
56-29	10847-10851	i.e.	_
56-30	10852-10853	,	_
56-31	10854-10857	Red	_
56-32	10858-10861	Cue	_
56-33	10862-10866	over	_
56-34	10867-10872	Green	_
56-35	10873-10884	Cue-related	_
56-36	10885-10893	activity	_
56-37	10894-10895	)	_
56-38	10896-10897	,	_
56-39	10898-10900	as	_
56-40	10901-10904	the	_
56-41	10905-10913	cellular	_
56-42	10914-10919	model	_
56-43	10920-10928	suggests	_
56-44	10929-10933	that	_
56-45	10934-10935	a	_
56-46	10936-10942	modest	_
56-47	10943-10951	decrease	_
56-48	10952-10954	in	_
56-49	10955-10960	tonic	_
56-50	10961-10967	firing	_
56-51	10968-10973	rates	_
56-52	10974-10980	should	_
56-53	10981-10983	be	_
56-54	10984-10994	associated	_
56-55	10995-10999	with	_
56-56	11000-11002	an	_
56-57	11003-11012	increased	_
56-58	11013-11019	phasic	_
56-59	11020-11021	(	_
56-60	11022-11026	i.e.	_
56-61	11027-11028	,	_
56-62	11029-11041	task-related	_
56-63	11042-11043	)	_
56-64	11044-11050	firing	_
56-65	11051-11055	rate	_
56-66	11056-11057	,	_
56-67	11058-11060	as	_
56-68	11061-11063	an	_
56-69	11064-11074	expression	_
56-70	11075-11077	of	_
56-71	11078-11082	gain	_
56-72	11083-11090	control	_
56-73	11091-11093	in	_
56-74	11094-11100	neural	_
56-75	11101-11109	activity	_
56-76	11110-11111	.	_

57-1	11112-11116	This	_
57-2	11117-11125	contrast	_
57-3	11126-11130	also	_
57-4	11131-11137	tested	_
57-5	11138-11141	the	_
57-6	11142-11152	hypothesis	_
57-7	11153-11157	that	_
57-8	11158-11167	elsewhere	_
57-9	11168-11170	in	_
57-10	11171-11174	the	_
57-11	11175-11184	cognitive	_
57-12	11185-11192	control	_
57-13	11193-11200	network	_
57-14	11201-11202	,	_
57-15	11203-11206	the	_
57-16	11207-11211	drug	_
57-17	11212-11217	would	_
57-18	11218-11220	be	_
57-19	11221-11231	associated	_
57-20	11232-11236	with	_
57-21	11237-11238	a	_
57-22	11239-11252	significantly	_
57-23	11253-11260	greater	_
57-24	11261-11272	enhancement	_
57-25	11273-11275	of	_
57-26	11276-11284	positive	_
57-27	11285-11300	control-related	_
57-28	11301-11305	BOLD	_
57-29	11306-11312	signal	_
57-30	11313-11319	change	_
57-31	11320-11321	,	_
57-32	11322-11327	again	_
57-33	11328-11336	compared	_
57-34	11337-11339	to	_
57-35	11340-11347	placebo	_
57-36	11348-11349	.	_

58-1	11350-11353	All	_
58-2	11354-11362	contrast	_
58-3	11363-11367	maps	_
58-4	11368-11371	are	_
58-5	11372-11380	depicted	_
58-6	11381-11383	at	_
58-7	11384-11385	a	_
58-8	11386-11395	threshold	_
58-9	11396-11398	of	_
58-10	11399-11400	p	_
58-11	11401-11402	<	_
58-12	11403-11407	0.05	_
58-13	11408-11409	,	_
58-14	11410-11414	with	_
58-15	11415-11423	clusters	_
58-16	11424-11433	corrected	_
58-17	11434-11436	to	_
58-18	11437-11438	p	_
58-19	11439-11440	<	_
58-20	11441-11445	0.05	_
58-21	11446-11448	by	_
58-22	11449-11461	small-volume	_
58-23	11462-11463	(	_
58-24	11464-11467	for	_
58-25	11468-11470	LC	_
58-26	11471-11474	and	_
58-27	11475-11478	VTA	_
58-28	11479-11480	)	_
58-29	11481-11483	or	_
58-30	11484-11487	the	_
58-31	11488-11493	False	_
58-32	11494-11503	Discovery	_
58-33	11504-11508	Rate	_
58-34	11509-11510	(	_
58-35	11511-11514	for	_
58-36	11515-11518	the	_
58-37	11519-11527	cortical	_
58-38	11528-11537	cognitive	_
58-39	11538-11545	control	_
58-40	11546-11553	network	_
58-41	11554-11555	)	_
58-42	11556-11557	.	_

59-1	11558-11562	Code	_
59-2	11563-11575	availability	_
59-3	11576-11579	All	_
59-4	11580-11592	neuroimaging	_
59-5	11593-11597	data	_
59-6	11598-11612	pre-processing	_
59-7	11613-11616	and	_
59-8	11617-11625	analyses	_
59-9	11626-11630	were	_
59-10	11631-11640	conducted	_
59-11	11641-11646	using	_
59-12	11647-11651	SPM5	_
59-13	11652-11660	software	_
59-14	11661-11662	,	_
59-15	11663-11668	which	_
59-16	11669-11671	is	_
59-17	11672-11679	readily	_
59-18	11680-11689	available	_
59-19	11690-11692	in	_
59-20	11693-11696	the	_
59-21	11697-11703	public	_
59-22	11704-11710	domain	_
59-23	11711-11712	.	_

60-1	11713-11716	See	_
60-2	11717-11720	the	_
60-3	11721-11733	Supplemental	_
60-4	11734-11741	Methods	_
60-5	11742-11745	for	_
60-6	11746-11753	details	_
60-7	11754-11756	of	_
60-8	11757-11769	localization	_
60-9	11770-11772	of	_
60-10	11773-11776	the	_
60-11	11777-11779	LC	_
60-12	11780-11781	,	_
60-13	11782-11785	VTA	_
60-14	11786-11789	and	_
60-15	11790-11799	cognitive	_
60-16	11800-11807	control	_
60-17	11808-11815	network	_
60-18	11816-11818	in	_
60-19	11819-11822	EPI	_
60-20	11823-11829	images	_
60-21	11830-11831	,	_
60-22	11832-11835	and	_
60-23	11836-11847	correlation	_
60-24	11848-11856	analysis	_
60-25	11857-11859	of	_
60-26	11860-11864	BOLD	_
60-27	11865-11871	signal	_
60-28	11872-11878	change	_
60-29	11879-11883	with	_
60-30	11884-11897	antipsychotic	_
60-31	11898-11914	receptor-binding	_
60-32	11915-11925	affinities	_
60-33	11926-11927	.	_

